Nigel Fleeman

1.8k total citations
61 papers, 1.3k citations indexed

About

Nigel Fleeman is a scholar working on Pediatrics, Perinatology and Child Health, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nigel Fleeman has authored 61 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pediatrics, Perinatology and Child Health, 13 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nigel Fleeman's work include Pharmacological Effects and Toxicity Studies (9 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Epilepsy research and treatment (7 papers). Nigel Fleeman is often cited by papers focused on Pharmacological Effects and Toxicity Studies (9 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Epilepsy research and treatment (7 papers). Nigel Fleeman collaborates with scholars based in United Kingdom, Switzerland and United States. Nigel Fleeman's co-authors include Y Dündar, Angela Boland, Peter Bradley, A Bagust, Rumona Dickson, C McLeod, Bruce Lindsay, J Greenhalgh, Sophie Beale and T Walley and has published in prestigious journals such as Cochrane Database of Systematic Reviews, Behaviour Research and Therapy and Environmental Research Letters.

In The Last Decade

Nigel Fleeman

54 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nigel Fleeman United Kingdom 23 219 198 186 165 151 61 1.3k
Vanessa Rousseau France 21 226 1.0× 163 0.8× 197 1.1× 124 0.8× 45 0.3× 103 1.4k
Spiros Vamvakas Germany 29 169 0.8× 88 0.4× 204 1.1× 195 1.2× 113 0.7× 63 2.0k
Catherine Copley‐Merriman United States 22 176 0.8× 70 0.4× 202 1.1× 95 0.6× 29 0.2× 68 1.7k
Laura Williams United States 20 319 1.5× 234 1.2× 108 0.6× 451 2.7× 45 0.3× 58 2.6k
Alun Bedding United Kingdom 16 167 0.8× 335 1.7× 57 0.3× 69 0.4× 52 0.3× 32 1.3k
Andrea Zuckerman United States 18 194 0.9× 98 0.5× 158 0.8× 66 0.4× 28 0.2× 32 2.4k
Larry E. Fields United States 17 94 0.4× 48 0.2× 221 1.2× 80 0.5× 44 0.3× 31 2.7k
Nikki M. Carroll United States 24 245 1.1× 170 0.9× 330 1.8× 104 0.6× 21 0.1× 60 1.5k
Sanjay Gandhi United States 25 566 2.6× 106 0.5× 135 0.7× 64 0.4× 27 0.2× 118 2.6k
K. Jack Ishak United States 21 209 1.0× 225 1.1× 507 2.7× 120 0.7× 16 0.1× 43 2.0k

Countries citing papers authored by Nigel Fleeman

Since Specialization
Citations

This map shows the geographic impact of Nigel Fleeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel Fleeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel Fleeman more than expected).

Fields of papers citing papers by Nigel Fleeman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nigel Fleeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel Fleeman. The network helps show where Nigel Fleeman may publish in the future.

Co-authorship network of co-authors of Nigel Fleeman

This figure shows the co-authorship network connecting the top 25 collaborators of Nigel Fleeman. A scholar is included among the top collaborators of Nigel Fleeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nigel Fleeman. Nigel Fleeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fleeman, Nigel, Rachel Houten, Sarah J Nevitt, et al.. (2024). Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 28(49). 1–190.
2.
Puzzolo, Elisa, Nigel Fleeman, Yaojie Li, et al.. (2024). Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses. The Lancet Respiratory Medicine. 12(4). 281–293. 32 indexed citations
3.
4.
Bresnahan, Rebecca, Rachel Houten, J Greenhalgh, et al.. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open. 7(4). 525–536.
5.
Chaplin, Marty, Rebecca Bresnahan, Nigel Fleeman, et al.. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open. 7(6). 863–875. 6 indexed citations
6.
7.
Fleeman, Nigel, Rachel Houten, A Bagust, et al.. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Health Technology Assessment. 24(2). 1–180. 30 indexed citations
8.
Stainthorpe, Angela, Nigel Fleeman, Rachel Houten, et al.. (2020). Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open. 4(4). 563–574. 3 indexed citations
9.
Houten, Rachel, et al.. (2020). A systematic review of health state utility values for thyroid cancer. Quality of Life Research. 30(3). 675–702. 19 indexed citations
10.
Fleeman, Nigel, Rachel Houten, Marty Chaplin, et al.. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer. 19(1). 1209–1209. 34 indexed citations
11.
Fleeman, Nigel, James Mahon, Sarah J Nevitt, et al.. (2019). Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open. 3(4). 453–461. 22 indexed citations
12.
Fleeman, Nigel, A Bagust, Rui Duarte, et al.. (2019). Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open. 3(3). 293–302. 1 indexed citations
13.
Fleeman, Nigel, et al.. (2019). Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis. International Journal of Technology Assessment in Health Care. 35(4). 298–306. 23 indexed citations
14.
15.
Fleeman, Nigel, A Bagust, Angela Boland, et al.. (2017). Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 35(10). 1035–1046. 6 indexed citations
16.
Protogerou, Cleo, Nigel Fleeman, Kerry Dwan, et al.. (2015). Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis. Behaviour Research and Therapy. 73. 151–164. 29 indexed citations
17.
Fleeman, Nigel, A Bagust, Sophie Beale, et al.. (2014). Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. PharmacoEconomics. 33(1). 13–23. 18 indexed citations
18.
Fleeman, Nigel, C Martin Saborido, Katherine Payne, et al.. (2011). The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.. Health Technology Assessment. 15(33). 1–102. 41 indexed citations
19.
20.
Bagust, A, J Greenhalgh, Angela Boland, et al.. (2010). Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. PharmacoEconomics. 28(6). 439–448. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vanessa Rousseau Breakdown of academic impact, for papers by Spiros Vamvakas Breakdown of academic impact, for papers by Catherine Copley‐Merriman Breakdown of academic impact, for papers by Laura Williams Breakdown of academic impact, for papers by Alun Bedding Breakdown of academic impact, for papers by Andrea Zuckerman Breakdown of academic impact, for papers by Larry E. Fields Breakdown of academic impact, for papers by Nikki M. Carroll Breakdown of academic impact, for papers by Sanjay Gandhi Breakdown of academic impact, for papers by K. Jack Ishak
Rankless by CCL
2026